The ARDAT (Accelerating Research and Development for ATMPs) project held its Final General Assembly Meeting (GAM) on April 20–21, 2026, hosted by Bayer in Berlin, Germany. The meeting brought together partners both in person and online to review progress across work packages, with a strong focus on delivering key outputs in the final months of the project.
Significant advances have been made toward ARDAT’s core objectives, particularly in developing data and tools to address knowledge gaps in areas such as AAV intracellular metabolism and cellular immunogenicity—efforts that are expected to accelerate research and development of Advanced Therapy Medicinal Products (ATMPs).
The assembly was marked by engaging discussions, a wealth of ideas, and overwhelmingly positive feedback, underscoring the project’s lasting impact and promising future despite its conclusion.
Thanks to all those that contributed to making this final meeting a great success!
